Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
GABA modulatorbenzodiazepines, zolpidem, zopiclone +2 morebenzodiazepines, zolpidem, zopiclone, alcohol, barbiturates show less
Flunitrazolam
Flunitrazolam is a synthetic depressant of the triazolobenzodiazepine class. It is the direct triazole structural analog of flunitrazepam (Rohypnol), approximately ten times more potent.[1] It amplifies GABA, the brain's primary calming signal, producing deep sedation and the other hallmark effects of the class.[2][3]
Flunitrazolam is a synthetic depressant of the triazolobenzodiazepine class. It is the triazole structural analog of flunitrazepam (Rohypnol), with approximately ten-fold greater potency.[1] Flunitrazolam is a positive allosteric modulator at GABA-A receptors, producing its effects by amplifying the brain's primary inhibitory signaling system.[2][3]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
GABA modulatorbenzodiazepines, zolpidem, zopiclone +2 morebenzodiazepines, zolpidem, zopiclone, alcohol, barbiturates show less
First identified in October 2016 by a German analytical laboratory, flunitrazolam has no pharmaceutical history and was never developed for medical use.[4] It entered online research chemical markets as tablets, blotters, and powder, and was quickly detected in poisoning cases across Europe alongside synthetic opioids.[5][6] The UK banned it in 2021; the United States has not scheduled it.[7]
Subjective effects include heavy sedation, anterograde amnesia — inability to form new memories — anxiety relief, muscle relaxation, and disinhibition. The experience is defined by an unusually deep amnesia that outstrips the sedation: a person may remain mobile and conversational while forming no memories of what they are doing. Delusions of sobriety and compulsive redosing are characteristic unsought effects.[2]
Flunitrazolam carries high abuse liability, and no lethal dose has been established for the compound in any species.safety citation needed Combining it with opioids or alcohol dramatically amplifies respiratory depression — a pattern documented in clinical poisoning cases.[5] The evidence base is extremely thin: what is known comes from a single self-administration study, in vitro metabolic work, and forensic case series.[8]
History[edit]
Discovery
Flunitrazolam was first identified in October 2016, when a German laboratory reported it to the European Early Warning System.[4][9] No prior scientific description existed. Its design followed established logic: fusing a triazole ring onto flunitrazepam, the same structural move that separates alprazolam from diazepam.[2][10]
Market appearance and detection
It entered online markets as pink tablets, blotters, and powder, and by 2016–2017 was being detected in poisoning cases in Sweden — including five of eleven acrylfentanyl presentations.[5][6] By 2020, it ranked fourth among tracked designer benzodiazepines by EU seizure count.[11]
Regulatory response
The UK banned it in August 2021, with the advisory council explicitly citing drug-facilitated sexual assault as a concern.[7] Germany, Canada, and Belgium have also controlled it.[4][12]
The name flunitrazolam is systematic: flu (fluorine), nitra (nitro group), zolam (triazolobenzodiazepine class suffix). Its parent compound Flunitrazepam — marketed as Rohypnol — carries one of the most recognized reputations in drug culture as a date-rape drug. Flunitrazolam inherits and intensifies that association; the UK advisory council explicitly cited sexual assault potential in its scheduling rationale.[7]
Chemistry[edit]
Structural class
Flunitrazolam belongs to the triazolobenzodiazepine class — benzodiazepines with a fused triazole ring, shared with alprazolam and clonazolam, that consistently increases potency over the parent compound.[2][10] It is the direct triazole structural analog of flunitrazepam, retaining flunitrazepam's fluorine and nitro groups while adding the triazole ring; the fluorine improves membrane crossing, and the nitro group influences both binding and metabolism.[13]
Molecular properties
Its molecular formula is C₁₇H₁₂FN₅O₂ (337.31 g/mol). Flunitrazolam is a yellow crystalline powder.[14] The nitro group is vulnerable to bacterial breakdown in unpreserved biological samples, which complicates forensic testing.[15]
Pharmacology[edit]
Mechanism of action
Flunitrazolam amplifies GABA, the brain's primary calming neurotransmitter, by binding to GABA receptors and increasing how often their channel opens.[2][3] The UK advisory council assessed its potency as likely exceeding that of flunitrazepam — already the most potent marketed clinical benzodiazepine.[7] No specific binding affinity values have been published for flunitrazolam — a significant gap for a compound of this potency.
Pharmacokinetics
The only controlled human data come from a self-administration study in which a researcher ingested one confirmed 0.25 mg tablet.[8] Effects begin within 20–40 minutes of oral ingestion. The body breaks flunitrazolam down primarily by converting its nitro group to an amino compound, with additional steps that appear to require multiple enzymes — a pattern that may cause the drug to last much longer in some people than others.[13][16]
The parent compound was detectable in urine for up to 21 hours; metabolites extended detection to 37 hours.[8] The half-life is estimated at 5–13 hours in secondary sources, but no plasma study has confirmed this.safety citation needed
Neuroscience[edit]
Where it acts
Flunitrazolam amplifies inhibitory signaling across multiple brain circuits simultaneously.[3][2] In the hippocampus it disrupts memory formation, producing the defining amnesia. In brainstem breathing centers, the same suppression of activity slows breathing drive — the mechanism behind potentially lethal respiratory depression.[17]
Why it matters
Flunitrazolam triggers a dopamine surge in reward circuits by suppressing brain cells that normally keep dopamine in check.[3] High-potency, short-acting compounds produce sharper surges, driving stronger reinforcement and compulsive redosing. With repeated use, the brain compensates by reducing the responsiveness of its calming system — setting the stage for tolerance and, if use stops abruptly, withdrawal seizures.
No neuroimaging or electrophysiology studies have been conducted with flunitrazolam. Whether ultra-potent designer benzodiazepines accelerate the brain's compensatory changes — producing faster tolerance and more severe withdrawal — remains unknown. The unusual metabolic profile[16] also raises the possibility that the drug's duration varies more between individuals than is typical for the class.
Subjective Effects[edit]
Flunitrazolam produces a heavy, cognitively suppressive experience dominated by sedation and a pervasive erasure of short-term memory. The amnesia is disproportionate — at common doses a person may remain upright and conversational while forming no memories of what they are doing. The experience is defined by what it removes.
Within the triazolobenzodiazepine class, flunitrazolam most closely resembles triazolam and clonazolam — rapid onset, heavy sedation, pronounced amnesia, steep dose-response — but at substantially lower absolute doses. The compulsive redosing pattern that emerges from the convergence of amnesia, delusions of sobriety, and perceived underdosing is a consistently identified distinctive hazard.[2]
First identified by an analytical laboratory in Germany in October 2016, flunitrazolam has no pharmaceutical history and was never developed for clinical use.[4] It entered online research chemical markets as tablets, blotters, and powder, and was soon detected in clinical poisoning cases across Europe — often alongside synthetic opioids.[5][6] Several jurisdictions have since scheduled the compound, including the UK as Class C,[7] though it remains unscheduled by the US DEA.
Subjective effects include sedation, anterograde amnesia, anxiolysis, muscle relaxation, and disinhibition. The experience is defined by an unusually deep amnesia that can outstrip the perceived level of sedation — users may remain mobile and conversational while forming no memories, a dissociation between function and recall that makes the compound particularly unpredictable. Delusions of sobriety and compulsive redosing are characteristic unsought effects.[2]
Flunitrazolam carries high abuse liability,[3] and no lethal dose, therapeutic index, or controlled toxicity data have been established.safety citation needed Respiratory depression is the primary acute lethal risk, amplified dramatically by co-ingestion of opioids or alcohol — a pattern documented in clinical poisoning cases.[5] The published evidence rests on a single self-administration pharmacokinetic study,[8] in vitro metabolism work, and forensic case series — no clinical trials or binding affinity data exist.
History[edit]
Discovery
Flunitrazolam was first identified in October 2016, when a German analytical laboratory reported it to the EMCDDA Early Warning System.[4][9] No prior description existed in scientific or patent literature, and no synthesizer has been identified — the compound emerged entirely from clandestine production. Its design followed a well-established structural logic: fusing a triazole ring onto flunitrazepam, mirroring the relationship between alprazolam and diazepam, or between clonazolam and clonazepam.[2][10]
Market appearance and detection
Flunitrazolam entered online research chemical markets shortly after identification, sold as pink tablets (typically labeled 0.25 mg), blotters, pellets, and loose powder. By 2016–2017, the Swedish STRIDA project — a national system for monitoring new psychoactive substance poisonings — detected it in clinical intoxication cases, including five of eleven acrylfentanyl poisoning presentations.[5][6] By 2020, flunitrazolam accounted for 58 seizure incidents across the European Union, ranking fourth among tracked designer benzodiazepines.[11] In the United States, novel benzodiazepines including flunitrazolam were identified in whole blood specimens at the New York City Medical Examiner's office.[12]
Regulatory response
The combination of sub-milligram dosing, extreme potency, and documented clinical harms triggered scheduling across multiple jurisdictions. The UK Advisory Council on the Misuse of Drugs assessed flunitrazolam among 11 designer benzodiazepines and explicitly referenced the potential for drug-facilitated sexual assault in its scheduling rationale, placing the compound under Class C of the Misuse of Drugs Act 1971 effective August 2021.[7] Germany controls it under its NpSG blanket legislation, Canada lists it under Schedule IV, and Belgium added it to Annex IVB in 2023.[4][13]
The name flunitrazolam is a systematic compound: flu (fluorine substituent), nitra (nitro group), zolam (triazolobenzodiazepine class suffix). The -zolam ending places it in the same naming lineage as Alprazolam, triazolam, and Clonazolam. Its parent compound Flunitrazepam — marketed as Rohypnol — carries one of the most recognized reputations in drug culture as a date-rape drug. Flunitrazolam inherits and intensifies that association: the UK ACMD's scheduling rationale explicitly cited drug-facilitated sexual assault potential as a factor.[7]
Chemistry[edit]
Structural class
Flunitrazolam belongs to the triazolobenzodiazepine subclass — benzodiazepines with a fused 1,2,4-triazole ring. This triazole fusion is the structural feature shared with alprazolam, triazolam, and clonazolam, and it consistently increases potency relative to the parent compound.[2][10]
Flunitrazolam is the direct triazole structural analog of flunitrazepam (Rohypnol). It retains flunitrazepam's two key substituents — a fluorine-bearing phenyl ring and a nitro group — while adding the triazole ring that defines the -zolam class. The fluorine increases the compound's ability to cross cell membranes; the nitro group influences both receptor binding and how the body metabolizes the drug.[14]
Molecular properties
| Molecular formula | C₁₇H₁₂FN₅O₂ |
| Molecular weight | 337.31 g/mol |
The core structure is a fused three-ring system: a benzene ring, a seven-membered diazepine ring, and the 1,2,4-triazole ring. A fluorine-bearing phenyl group projects from the diazepine ring. The molecule contains five nitrogen atoms distributed across the triazole and diazepine rings.
Stereochemistry
Flunitrazolam lacks a stereocenter in its standard form. Unlike some benzodiazepines where a hydroxyl group at the C3 position creates chirality, flunitrazolam's C3 is part of the fused triazole ring and does not produce separable mirror-image forms.[14]
Physical properties
Flunitrazolam presents as a yellow crystalline powder.[15] It dissolves readily in organic solvents but is expected to have low water solubility based on its lipophilic character. No stability studies under ambient storage conditions have been reported. The nitro group is susceptible to bacterial reduction in unpreserved biological samples — a finding with significant implications for forensic sample handling.[16]
Pharmacology[edit]
Mechanism of action
Flunitrazolam enhances the activity of GABA, the brain's primary inhibitory neurotransmitter. It binds to the benzodiazepine site on GABA-A receptors — a site located between the α and γ₂ subunits of the receptor complex — and increases the frequency with which the receptor's chloride channel opens in response to GABA.[2][3] The compound does not activate the receptor on its own; it amplifies GABA's existing signal.
This amplified inhibitory signaling produces the characteristic benzodiazepine effects: sedation, anxiety reduction, muscle relaxation, seizure suppression, and amnesia. The triazole ring modification that distinguishes flunitrazolam from its parent compound flunitrazepam increases the molecule's lipophilicity and modifies how it interacts with the receptor, producing a more potent effect.[10][2]
The UK Advisory Council on the Misuse of Drugs assessed that flunitrazolam's potency likely exceeds that of flunitrazepam — itself the most potent marketed clinical benzodiazepine.[7] In laboratory tests on rat cortical neurons, flunitrazolam inhibited spontaneous network activity at concentrations as low as 0.01 µM.[1] No specific binding affinity values have been published for flunitrazolam at any GABA-A receptor subtype — a significant gap for a compound of this potency.
Pharmacokinetics
The only controlled human pharmacokinetic data come from a single self-administration study in which a researcher ingested one confirmed 0.25 mg tablet.[8]
Absorption and onset: Flunitrazolam is taken orally in tablets, blotters, or pellets. Effects begin within 20–40 minutes of ingestion. No bioavailability data have been published.
Metabolism: The body processes flunitrazolam through multiple pathways. The primary route is reduction of the nitro group to an amino compound (7-amino-flunitrazolam), confirmed in both liver cell studies and the self-administration study.[14][8] Additional pathways include hydroxylation and glucuronide conjugation. The glucuronidation pathway is pharmacologically unusual: unlike most designer benzodiazepines, which are conjugated by a single enzyme, flunitrazolam appears to require the coordinated action of multiple enzymes for this step.[17] This may contribute to variation in how quickly different individuals eliminate the drug.
Elimination: In the self-administration study, the parent compound was detectable in urine for up to 21 hours, with approximately 3% of the dose excreted unchanged.[8] Metabolites extended the detection window to 37 hours when specifically targeted. The half-life has been estimated at 5–13 hours in secondary sources, but no controlled plasma pharmacokinetic study has confirmed this.safety citation needed
Neuroscience[edit]
Where it acts
Flunitrazolam amplifies inhibitory signaling across distributed brain circuits. In the cortex and thalamus, enhanced GABA activity suppresses arousal-related information flow, producing sedation. In the hippocampus, it disrupts the cellular mechanism of memory formation (long-term potentiation), producing the compound's defining anterograde amnesia. In the amygdala and limbic circuits, it dampens threat reactivity, producing anxiolysis.[3][2] In brainstem respiratory centers, this same amplification of inhibition suppresses breathing drive — the mechanism underlying the potentially lethal respiratory depression.[18] Laboratory studies on cortical neuron networks demonstrated that flunitrazolam suppresses spontaneous activity at concentrations as low as 0.01 µM.[1]
Why it matters
Flunitrazolam's reinforcement potential arises from a specific circuit: it enhances inhibition of interneurons in the ventral tegmental area that normally restrain dopamine release. The result is a surge of dopamine in reward circuits. High-potency, short-acting compounds produce sharper peaks in this dopamine signal, contributing to stronger reinforcement and compulsive redosing.[3] With repeated use, the brain compensates by downregulating GABA-A receptors and sensitizing excitatory glutamate systems — producing tolerance and setting the stage for withdrawal seizures if use stops abruptly.
No neuroimaging or electrophysiology studies have been conducted with flunitrazolam. Whether it preferentially binds to the receptor subtypes responsible for sedation and amnesia (α₁-containing GABA-A receptors), rather than those mediating anxiety relief, is unknown. Whether ultra-potent designer benzodiazepines accelerate the brain's compensatory neuroplastic changes — and thus produce faster tolerance and more severe withdrawal — compared to lower-potency compounds remains an open question. The unusual metabolic profile[17] also raises the possibility that flunitrazolam's duration of action varies more between individuals than is typical for the class.
Subjective Effects[edit]
Flunitrazolam produces a subjective experience dominated by heavy sedation, cognitive suppression, and a pervasive erasure of short-term memory formation. The amnestic effect is disproportionately potent relative to the sedative load: at common doses, users may retain enough motor function to act, speak, and redose while forming no memories of doing so. Set and setting exert less influence than with many psychoactive substances — the pharmacological profile overwhelms contextual factors at common-to-strong doses.
Within the triazolobenzodiazepine class, flunitrazolam's experiential signature most closely resembles triazolam and clonazolam — rapid onset, heavy sedation, pronounced amnesia, steep dose-response — but at substantially lower absolute doses. The compulsive redosing pattern, driven by the convergence of amnesia, delusions of sobriety, and perceived underdosing, is consistently highlighted as a distinctive hazard.[2]
Effect Grid
Clear sedation dominates the experience alongside marked anxiety suppression and muscle relaxation. Anterograde amnesia becomes apparent — memory of events during exposure is patchy and unreliable. Cognitive processing is noticeably slowed, with analysis suppression and information processing suppression clearly present. Emotional suppression flattens affective range.
Physical effects include moderate motor control impairment, bodily heaviness, and mild dizziness. Physical fatigue may encourage lying down. Respiratory depression remains subclinical at this dose in healthy individuals but is dose-dependent.
Disinhibition is present and delusions of sobriety may begin — users may believe they are less impaired than they are. Compulsive redosing risk increases as amnesia impairs recall of prior doses. This is the dose range where the defining risk pattern of flunitrazolam emerges: ambulatory blackout with continued redosing.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual acuity suppression · Dreaming enhancement
Physical fatigue · Dizziness · Body high · Insomnia · Nystagmus (eye wobbles) · Sexual arousal suppression · Laughter fits · Nausea · Nausea suppression · Restlessness · Seizure threshold reduction · Bodily dissociation
Insomnia · Nystagmus (eye wobbles) · Sexual arousal suppression · Laughter fits · Nausea · Nausea suppression · Restlessness · Bodily dissociation
Cognitive fatigue · Focus suppression · Memory suppression · Thought deceleration · Creativity suppression · Memory fragmentation · Motivation suppression · Thought disorganization · Confusion · Language suppression · Suggestibility enhancement · Compulsive redosing urge · Humor enhancement · Cognitive dysphoria · Amnesia · Delirium
Thought deceleration · Creativity suppression · Memory fragmentation · Motivation suppression · Thought disorganization · Confusion · Language suppression · Compulsive redosing urge · Humor enhancement · Cognitive dysphoria · Amnesia · Delirium
Empathy suppression · Dysphoria · Emotional lability · Irritability · Anxiety · Anhedonia
Anxiety · Anhedonia
Emotional susceptibility · Sociability suppression · Trust enhancement · Communication enhancement · Sociability enhancement · Depersonalization · Derealization
Sociability enhancement · Depersonalization · Derealization
Timeline
Absorption period with no perceptible effects initially. A faint awareness that something has shifted may emerge toward the end of this phase.
Anxiolysis and mild relaxation become noticeable. Subtle sedation and muscle loosening emerge as GABA-A potentiation builds.
Maximum sedation, anterograde amnesia, muscle relaxation, and anxiolysis. Cognitive suppression and disinhibition at their strongest. Delusions of sobriety may prevent self-assessment of impairment.
Gradual reduction in sedation. Cognitive impairment and memory gaps may persist beyond subjective awareness that peak effects have passed. Motor impairment lingers.
Residual sedation, cognitive fog, and possible next-day drowsiness. Memory of the experience may be incomplete or absent.
⚠ Do not drive or operate heavy machinery for at least 12 hours after ingestion — residual cognitive and motor impairment may persist beyond subjective awareness of drug effects.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Moderate
- Withdrawal
- Life-threateningfatal risk
- Tolerance buildup
- rapid
- Tolerance reset
- 10.5 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- High
- Cross-tol.
- benzodiazepines · zolpidem · zopiclone
Toxicity
Acute toxicity
No lethal dose data exist for flunitrazolam, and no therapeutic index has been calculated.safety citation needed The primary risk is respiratory depression — breathing slows and can stop — at doses above the intended range, especially in combination with other depressants. The sub-milligram dosing range means that milligram-scale weighing errors can produce two- to five-fold dose escalation.[2][9]
Clinical intoxication data
Flunitrazolam has appeared in poisoning cases across multiple countries. In Sweden, it was detected in five of eleven acrylfentanyl poisoning presentations, with patients showing decreased consciousness and respiratory depression.[5][6] It has also been found in emergency ward admissions in Sweden[18] and in whole blood specimens at the New York City Medical Examiner's office.[19]
Fatalities
No case report attributes death specifically to flunitrazolam alone. It has been identified as a co-intoxicant in polydrug fatality investigations.[5] The absence of standalone fatality reports likely reflects detection gaps and the compound's recency — not safety.
Chronic toxicity
No data address organ-specific chronic toxicity for flunitrazolam. Class-level concerns include liver burden, cognitive impairment, and brain changes underlying tolerance and dependence.[17]
Psychological risks
Anterograde amnesia — inability to form new memories during the experience — is the defining psychological risk, flagged by the ACMD as particularly concerning given flunitrazolam's relationship to flunitrazepam.[7] Delusions of sobriety — the conviction of being unimpaired while profoundly intoxicated — compound this by undermining self-monitoring.[2] People may drive or make consequential decisions without awareness of their impairment.
Compulsive redosing follows from the convergence of amnesia and delusions of sobriety, producing cumulative toxicity within a single session. Designer benzodiazepines with similar profiles have been detected in sexual assault cases;[20] the ACMD explicitly cited flunitrazolam's rapid incapacitation, profound amnesia, and short detection window as factors enabling drug-facilitated assault.[7]
Tolerance & dependence
Tolerance develops within days of continuous use as the brain reduces GABA receptor sensitivity and compensates by ramping up excitatory activity.[3] Cross-tolerance is complete with all other benzodiazepines, and partial with alcohol, z-drugs, and barbiturates. Dependence liability is expected to be high — high-potency, short-to-intermediate-acting benzodiazepines carry greater physical and psychological dependence risk than longer-acting compounds.[3]
Stopping abruptly after dependence has developed produces rebound effect anxiety, insomnia, tremor, sweating, and perceptual disturbances — and in severe cases, seizures and delirium that can be life-threatening. Management requires gradual dose reduction with a long-acting benzodiazepine such as diazepam.[3][21]
Drug Interactions
Opioids are the most dangerous documented combination — both classes suppress breathing through different mechanisms, and together they can cause respiratory failure at doses that would be survivable for either drug alone.[5] Alcohol acts similarly through dual GABA suppression; this combination is potentially fatal and is the most common dangerous co-exposure for benzodiazepines as a class.[2]
Other GABA-active depressants — other benzodiazepines, z-drugs, barbiturates, GHB — add or multiply the effect unpredictably. Stimulants may mask sedation, enabling dangerous redosing while respiratory suppression accumulates undetected. Drugs that inhibit CYP3A4 — including ketoconazole, ritonavir, and grapefruit juice — are expected to substantially raise flunitrazolam blood levels, based on structural analogy to alprazolam and triazolam.inferred
Contraindications
6 knownNo substance-specific contraindication data exist; the following are inferred from class pharmacology. Concurrent depressant use — opioids, alcohol, barbiturates, GHB, or other benzodiazepines — is an absolute contraindication; the synergistic respiratory depression documented in clinical cases can be fatal.[5] Respiratory conditions such as sleep apnea or COPD also elevate the risk of breathing failure.
Liver impairment may disproportionately prolong effects given the compound's complex multi-enzyme metabolism.[16] Pregnancy, history of substance use disorder, and myasthenia gravis are relative contraindications inferred from class pharmacology.inferred
Harm Reduction[edit]
Forms & Identification
Flunitrazolam's sub-milligram dose range makes standard field-testing severely limited. Standard benzodiazepine immunoassay panels may not detect designer benzodiazepines at all — in one study, 70% of immunoassay-positive but confirmation-negative blood samples contained at least one novel benzodiazepine.[19] Reagent testing confirms benzodiazepine-class presence but cannot identify which designer compound or verify the dose.
For loose powder, a standard milligram-precision scale is insufficient for the 0.1–0.5 mg range. Volumetric dosing — dissolving a known quantity in a measured volume of solvent — is the only practical approach to accurate sub-milligram dosing from powder. Pre-dosed tablets and blotters carry their own risks: declared doses may not match actual content.
Guidelines
- Test any material with available reagent kits to confirm benzodiazepine-class identity. Reagent tests cannot verify dose or distinguish between designer benzodiazepines.
- Use volumetric dosing for loose powder. Do not attempt to weigh sub-milligram doses on a standard milligram scale.
- Start at the lowest reported threshold dose. The steep dose-response curve means small increases produce large changes in effect.
- Write down the substance name, dose, and time of ingestion before effects begin. Amnesia will prevent recall of this information later.
- Arrange a sober sitter who understands the amnestic and disinhibiting properties of the compound.
- Secure all remaining supply, car keys, and anything that could enable harmful decisions during impairment.
- Do not combine with any depressant — opioids, alcohol, other benzodiazepines, GHB, or sleep medications.
- Do not plan to redose. If the urge arises, consult the written note of when the first dose was taken.
Set & Setting
Flunitrazolam's pharmacological profile severely limits the protective value of set and setting at common-to-strong doses. Amnesia and delusions of sobriety override the ability to self-monitor. A trusted, sober companion is the single most important environmental safeguard.
A sober sitter should be prepared to prevent redosing — the amnestic person will not remember having taken a dose — monitor breathing, and intervene if the person attempts to drive or leave a safe environment. All doses and times of administration should be written down before effects begin.
Aftercare & integration. Flunitrazolam's amnestic properties mean that much or all of the experience may be unrecoverable. Waking with no memory of hours of activity — sometimes discovering evidence of actions one cannot recall — can be distressing.
After use, prioritize sleep, hydration, and light nutrition. Residual grogginess and impaired coordination may persist beyond the subjective duration of effects. Do not drive or operate machinery until full alertness has returned.
If disturbing memory gaps emerge, speak with the sober companion or review any written records. If use has become a pattern rather than an isolated event, the aftercare phase is the appropriate time to assess that honestly.
Recovery & Support
Benzodiazepine dependence is a serious medical condition requiring supervised management. Stopping abruptly after physical dependence has developed risks life-threatening withdrawal seizures.[3][21]
Anyone seeking to stop regular benzodiazepine use should consult a physician experienced in benzodiazepine tapering. The standard approach is gradual dose reduction using a long-acting benzodiazepine such as diazepam, which may take weeks to months depending on duration and intensity of use.
Support resources include the SAMHSA National Helpline (1-800-662-4357, US), Benzodiazepine Information Coalition (benzoinfo.com), and local addiction medicine services. Peer communities focused specifically on benzodiazepine withdrawal can provide practical guidance from people who have navigated the process.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Breathing becomes slow, shallow, irregular, or stops
- Lips, fingertips, or skin turn blue or grey
- The person cannot be roused by voice or firm physical stimulation
- Seizures occur, especially in someone who has been using regularly and stopped abruptly
Immediate steps:
- Call emergency services immediately if breathing is compromised or the person is unresponsive.
- Place the person in the recovery position — on their side, airway clear — to prevent choking.
- Monitor breathing continuously. Begin rescue breathing if trained and breathing stops.
- Do not leave the person alone. Do not induce vomiting.
- If opioid co-ingestion is suspected, administer naloxone first — it reverses opioid-driven respiratory depression but will not reverse benzodiazepine effects.
What to tell the dispatcher: Name the substance (flunitrazolam, a designer benzodiazepine), the approximate dose and time of ingestion, any co-ingested substances, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Reversal agent: Flumazenil can reverse benzodiazepine sedation and respiratory depression.[22] It is administered in hospital settings only. Flumazenil may trigger seizures in benzodiazepine-dependent individuals and wears off faster than most benzodiazepines, requiring repeated doses. In polydrug overdoses involving opioids, administer naloxone first or alongside flumazenil.[5]
Legal Status[edit]
Flunitrazolam's legal status varies widely by country — several have enacted specific controls since 2016, while others rely on structural analog provisions or have not yet addressed it.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United Kingdom | Class C (Misuse of Drugs Act 1971); Schedule 1 (MDR 2001) | Effective 18 August 2021. Schedule 1 — the most restrictive tier — reflects no known legitimate medicinal use. Home Office licence required for possession[7] |
| Germany | Controlled under NpSG (Neue-psychoaktive-Stoffe-Gesetz) | Covered by blanket NPS legislation[4] |
| Canada | Schedule IV (Controlled Drugs and Substances Act) | Specific scheduling confirmed[4] |
| Belgium | Annex IVB | Added approximately April 2023[12] |
| United States | Not explicitly DEA-scheduled | Not included in the DEA's temporary scheduling orders that placed five other designer benzodiazepines into Schedule I (2022–2026). The Federal Analogue Act may apply if deemed substantially similar to a scheduled substance and intended for human consumptionsafety citation needed |
| Sweden | Detected in clinical settings (2016–2017) | Scheduling status not confirmed in available research[5] |
| Australia | Status unconfirmed | Not found in TGA database search |
Analogue considerations
In unscheduled jurisdictions, flunitrazolam may fall under analogue legislation. In the United States, the Federal Analogue Act extends Schedule I/II controls to substances substantially similar to a listed substance when intended for human consumption; flunitrazolam's structural relationship to flunitrazepam and pharmacological similarity to scheduled designer benzodiazepines provide potential grounds, though this is untested for this compound.citation needed
Legal status changes frequently and varies by jurisdiction. This is not legal advice — verify current status with a qualified legal professional.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Moderate
- Withdrawal
- Life-threateningfatal risk
- Tolerance buildup
- rapid
- Tolerance reset
- 10.5 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- High
- Cross-tol.
- benzodiazepines · zolpidem · zopiclone
Toxicity
Acute toxicity
No lethal dose data exist for flunitrazolam in any species, and no therapeutic index has been calculated.safety citation needed These are fundamental data gaps for a compound already in circulation at active doses.
The primary acute risk is respiratory depression at doses above the intended range, especially in combination with other depressants. The sub-milligram dosing range (0.1–0.5 mg) creates significant overdose risk from weighing errors alone — milligram-scale miscalculations can produce two- to five-fold dose escalation.[2][9] Unregulated tablets and blotters may be misdosed or adulterated.
Clinical intoxication data
Flunitrazolam has appeared in clinical intoxication cases across multiple countries. In Sweden, the STRIDA project detected it as a co-intoxicant in five of eleven acrylfentanyl poisoning cases, with patients presenting decreased consciousness and respiratory depression.[5] Separate STRIDA analyses confirmed its presence in other benzodiazepine-related poisoning presentations.[6]
It has also been detected in routine drug testing and emergency ward admissions in Sweden[19] and in whole blood specimens at the New York City Medical Examiner's office.[12] By 2020, flunitrazolam accounted for 58 seizure incidents across the EU, ranking fourth among tracked designer benzodiazepines.[11]
Fatalities
No published case reports attribute death specifically to flunitrazolam alone. The compound has been identified as a co-intoxicant in polydrug fatality investigations.[5] The absence of standalone fatality reports should not be interpreted as evidence of safety — it likely reflects detection gaps, the compound's recency, and the predominance of polydrug use in the populations where it circulates.
Chronic toxicity
No data address organ-specific chronic toxicity for flunitrazolam. Class-level concerns include liver burden from ongoing metabolism, cognitive impairment with chronic use, and the brain changes underlying tolerance and dependence.[18]
Psychological risks
Anterograde amnesia is the defining psychological risk. Flunitrazolam produces dose-dependent inability to form new memories during exposure that is characteristically profound. The ACMD flagged this property as particularly concerning given its structural relationship to flunitrazepam, the most clinically potent amnestic benzodiazepine.[7]
Delusions of sobriety — the paradoxical conviction of being unimpaired while profoundly intoxicated — are documented across high-potency designer benzodiazepines.[2] This impairs self-monitoring: users may drive, make consequential decisions, or interact socially without awareness of their functional impairment.
Compulsive redosing is driven by the convergence of amnesia (no memory of having dosed), delusions of sobriety (perceived underdosing), and short-to-intermediate duration. This pattern can produce cumulative toxicity across repeated doses within a single session.
Drug-facilitated sexual assault: Designer benzodiazepines with profiles similar to flunitrazolam have been detected in sexual assault cases.[20] The ACMD explicitly referenced this compound's potential for facilitating assault — citing its high potency, rapid incapacitation, profound amnesia, and short detection window.[7]
Tolerance & dependence
No flunitrazolam-specific tolerance or dependence studies have been published. The following is inferred from the well-characterized class pharmacology of benzodiazepines.[3]
Tolerance develops within days of continuous use as the brain downregulates GABA-A subunits and compensates by sensitizing excitatory glutamate systems. Cross-tolerance is complete with all other benzodiazepines, and partial with other GABA-active depressants including alcohol, z-drugs (zolpidem, zopiclone), and barbiturates.
Dependence liability is expected to be high. High-potency, short-to-intermediate-acting benzodiazepines (triazolam, alprazolam) carry higher physical and psychological dependence liability than longer-acting compounds, owing to more pronounced between-dose withdrawal and sharper reinforcement.[3]
Withdrawal: Abrupt discontinuation after physical dependence produces rebound effect anxiety, insomnia, tremor, sweating, perceptual disturbances, and in severe cases seizures and delirium. Withdrawal seizures can be life-threatening. Management requires gradual dose reduction with a long-acting benzodiazepine such as diazepam.[3][21]
Drug Interactions
No substance-specific interaction studies have been published. The following is based on class pharmacology and documented co-intoxication patterns.[2]
Opioids (including fentanyl analogues): The most dangerous documented combination. Flunitrazolam appeared alongside acrylfentanyl in five of eleven STRIDA intoxication cases.[5] Both drug classes suppress breathing through different mechanisms, and the combination produces respiratory failure at doses that would be survivable for either drug alone.
Alcohol: Synergistic depression through dual action on GABA-A receptors (benzodiazepine and ethanol sites) combined with ethanol's additional glutamate suppression.[2] This combination is potentially fatal and is the most common dangerous co-exposure pattern for benzodiazepines as a class.
Other GABA-active depressants (other benzodiazepines, z-drugs, barbiturates, GHB/GBL): Additive or synergistic effects produce unpredictable dose escalation. GHB carries particular risk due to its own steep dose-response curve.
CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, grapefruit juice): Based on structural analogy to alprazolam and triazolam, drugs that inhibit CYP3A4 would be expected to increase flunitrazolam levels in the body, potentially substantially. This has not been experimentally confirmed.inferred
Stimulants: Co-administration with stimulants (amphetamines, cocaine) may mask the subjective perception of sedation, enabling dangerous redosing while respiratory depression accumulates undetected.
Contraindications
6 knownNo flunitrazolam-specific contraindication studies exist. The following are inferred from class pharmacology and the documented intoxication profile.
Concurrent depressant use (absolute): Co-ingestion with opioids, alcohol, barbiturates, GHB, or other benzodiazepines. The synergistic respiratory depression documented in clinical cases[5] can be fatal.
Respiratory conditions (absolute): Individuals with chronic obstructive pulmonary disease, sleep apnea, or other conditions compromising breathing capacity face elevated risk of respiratory failure.
Liver impairment (relative): Flunitrazolam undergoes complex liver metabolism requiring multiple enzymes for glucuronidation.[17] Liver impairment may disproportionately prolong the drug's effects.
Pregnancy (relative): No reproductive toxicity data exist. General benzodiazepine concerns include birth defect risk in the first trimester, neonatal sedation, and neonatal withdrawal.inferred
History of substance use disorder (relative): The high reinforcement potential and compulsive redosing pattern elevate risk in individuals with a history of sedative or polysubstance use disorder.
Myasthenia gravis (relative): Benzodiazepine-induced muscle relaxation may worsen muscle weakness.inferred
Harm Reduction[edit]
Forms & Identification
Flunitrazolam's sub-milligram active dose range means that conventional field-testing approaches face severe limitations. Standard benzodiazepine immunoassay panels may not detect designer benzodiazepines at all — in one study, 70% of immunoassay-positive but confirmation-negative blood samples contained at least one novel benzodiazepine.[12] Reagent testing can confirm the presence of a benzodiazepine-class compound but cannot distinguish flunitrazolam from other designer benzodiazepines or verify dose accuracy.
For loose powder, a milligram-precision scale (0.001 g) is insufficient for safe dosing at the 0.1–0.5 mg range; a microgram-precision analytical balance would be required. Volumetric dosing — dissolving a known quantity in a measured volume of solvent — is the only practical approach to accurate sub-milligram dosing from powder. Pre-dosed forms (tablets, pellets, blotters) carry their own risks: declared doses may not match actual content, and no quality control applies to any available form.
Guidelines
- Test any material with available reagent kits to confirm benzodiazepine-class identity. Be aware that reagent tests cannot verify dose or distinguish between designer benzodiazepines.
- If working from powder, use volumetric dosing. Do not attempt to weigh sub-milligram doses on a standard milligram scale.
- Start at the lowest reported threshold dose. Flunitrazolam's steep dose-response curve means small increases produce large changes in effect.
- Write down the substance name, dose, and time of ingestion before effects begin. Amnesia will prevent recall of this information later.
- Arrange a sober sitter who understands the amnestic and disinhibiting properties of the compound.
- Secure all remaining substance supply, car keys, and anything that could enable harmful decisions during impairment.
- Do not combine with any other depressant — opioids, alcohol, other benzodiazepines, GHB, or sleep medications.
- Do not plan to redose. If the urge arises, consult the written note of when the first dose was taken.
Set & Setting
Flunitrazolam's pharmacological profile significantly limits the protective value of set and setting at common-to-strong doses. The amnesia and delusions of sobriety override the user's ability to self-monitor, making a trusted, sober companion the single most important environmental safeguard.
A sober sitter should be prepared to prevent redosing (the amnestic user will not remember having taken a dose), monitor breathing, and intervene if the user attempts to drive or leave a safe environment. All doses and the time of administration should be written down in a visible location before effects begin.
Aftercare & integration. Flunitrazolam's amnestic properties mean that much or all of the experience under its influence may be unrecoverable. Users frequently report waking with no memory of hours of activity, sometimes discovering evidence of actions they cannot recall. This memory gap can be distressing.
After use, prioritize sleep, hydration, and light nutrition. Residual grogginess and impaired coordination may persist beyond the subjective duration of effects. Do not drive or operate machinery until full alertness has returned.
If disturbing gaps in memory emerge, speak with the sober companion who was present or review any written records. If use has become a pattern rather than an isolated event, the aftercare phase is the appropriate time to honestly assess that trajectory.
Recovery & Support
Benzodiazepine dependence is a serious medical condition that requires supervised management. Abrupt discontinuation of flunitrazolam or any benzodiazepine after physical dependence has developed risks life-threatening withdrawal seizures.[3][21]
Anyone seeking to stop regular benzodiazepine use should consult a physician experienced in benzodiazepine tapering. The standard approach involves gradual dose reduction using a long-acting benzodiazepine such as diazepam. The tapering process may take weeks to months depending on the duration and intensity of use.
Support resources include the SAMHSA National Helpline (1-800-662-4357, US), Benzodiazepine Information Coalition (benzoinfo.com), and local addiction medicine services. Peer support communities focused specifically on benzodiazepine withdrawal exist online and can provide practical guidance from people who have navigated the process.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Breathing becomes slow, shallow, irregular, or stops
- Lips, fingertips, or skin turn blue or grey
- The person cannot be roused by voice or firm physical stimulation
- Seizures occur, especially in someone who has been using regularly and stopped abruptly
Immediate steps:
- Call emergency services immediately if breathing is compromised or the person is unresponsive.
- Place the person in the recovery position (on their side, airway clear) to prevent choking.
- Monitor breathing continuously. If breathing stops, begin rescue breathing if trained.
- Do not leave the person alone. Do not induce vomiting.
- If opioid co-ingestion is suspected, administer naloxone first — it reverses opioid-driven respiratory depression but will not reverse benzodiazepine effects.
What to tell the dispatcher: Name the substance (flunitrazolam, a designer benzodiazepine), the approximate dose and time of ingestion, any co-ingested substances, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Reversal agent: Flumazenil is a competitive antagonist that can reverse benzodiazepine-induced sedation and respiratory depression.[22] It is administered in hospital settings only. Flumazenil may trigger seizures in benzodiazepine-dependent individuals and wears off faster than most benzodiazepines, requiring repeated doses. In polydrug overdoses involving opioids, naloxone should be administered first or alongside flumazenil.[5]
Legal Status[edit]
Flunitrazolam occupies a patchwork legal status internationally. Several jurisdictions have enacted specific controls since its emergence in 2016, while others rely on structural analog provisions or have not yet addressed it. No jurisdiction has approved flunitrazolam for any medical, veterinary, or research purpose.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United Kingdom | Class C (Misuse of Drugs Act 1971); Schedule 1 (MDR 2001) | Effective 18 August 2021. Schedule 1 — the most restrictive tier — reflects no known legitimate medicinal use. Home Office licence required for possession[7] |
| Germany | Controlled under NpSG (Neue-psychoaktive-Stoffe-Gesetz) | Covered by blanket NPS legislation[4] |
| Canada | Schedule IV (Controlled Drugs and Substances Act) | Specific scheduling confirmed[4] |
| Belgium | Annex IVB | Added approximately April 2023[13] |
| United States | Not explicitly DEA-scheduled | Not included in the DEA's temporary scheduling orders that placed five other designer benzodiazepines into Schedule I (2022–2026). The Federal Analogue Act may apply if deemed substantially similar to a scheduled substance and intended for human consumptionsafety citation needed |
| Sweden | Detected in clinical settings (2016–2017) | Scheduling status not confirmed in available research[5] |
| Australia | Status unconfirmed | Not found in TGA database search |
Analogue considerations
In jurisdictions without specific scheduling, flunitrazolam may fall under analogue legislation. In the United States, the Federal Analogue Act extends Schedule I/II controls to substances "substantially similar" in chemical structure or pharmacological effect to a listed controlled substance, when intended for human consumption. Flunitrazolam's structural relationship to flunitrazepam (Schedule IV) and its pharmacological similarity to Schedule I designer benzodiazepines (clonazolam, flualprazolam, flubromazolam) provide potential grounds for prosecution, though the legal interpretation is case-specific and untested for flunitrazolam.citation needed
Frequently asked questions
What is Flunitrazolam?
Flunitrazolam is a designer triazolobenzodiazepine and the triazole analogue of flunitrazepam, active at sub-milligram oral doses. It acts as a GABA-A receptor positive allosteric modulator, first identified in Germany in 2016 with no pharmaceutical lineage.
How long does Flunitrazolam last?
Total duration by route of administration — Oral: 4 – 8 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for Flunitrazolam?
Psychedex publishes a dosage table for Flunitrazolam on this page covering these routes of administration: oral. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with Flunitrazolam?
The highest-severity documented interactions for Flunitrazolam: Opioids (Lethal), Alpha-2 adrenergic receptor antagonist (Dangerous), Antipsychotics (Dangerous), Atypical antipsychotics (Dangerous), Benzodiazepines (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is Flunitrazolam addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for Flunitrazolam: tolerance builds rapid; full reset takes 10.5 days; cross-tolerance develops with benzodiazepines, zolpidem, zopiclone, alcohol, barbiturates. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1] ^Wopken JP, Thornton JR, van Kleef RGDM, Westerink RHS (2026) Inhibitory effects of (synthetic) cannabinoids and (designer) benzodiazepines on spontaneously active neuronal networks of primary rat cortical cultures in vitro — Neurotoxicology doi:10.1016/j.neuro.2025.103379
- [2]
- [3]
- [4]
- [5]
- [6] ^abcBäckberg M, Pettersson Bergstrand M, Beck O, Helander A (2019) Occurrence and time course of NPS benzodiazepines in Sweden - results from intoxication cases in the STRIDA project. — Clinical Toxicology doi:10.1080/15563650.2018.1506130
references
- [1] ^abcWopken JP, Thornton JR, van Kleef RGDM, Westerink RHS (2026) Inhibitory effects of (synthetic) cannabinoids and (designer) benzodiazepines on spontaneously active neuronal networks of primary rat cortical cultures in vitro — Neurotoxicology doi:10.1016/j.neuro.2025.103379
- [2]
- [3]
- [4]
- [5]
- [6] ^abcBäckberg M, Pettersson Bergstrand M, Beck O, Helander A (2019) Occurrence and time course of NPS benzodiazepines in Sweden - results from intoxication cases in the STRIDA project. — Clinical Toxicology doi:10.1080/15563650.2018.1506130